Physician profile
Paige C Harris
NPI 1992957575
$464,826.40
in general payments reported to CMS, 2019-2025
65 companies · $152K in 2025
The $152K reported for 2025 was more than what 99% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $40K · 2022: $56K · 2023: $113K · 2024: $104K · 2025: $152K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $227K · Consulting Fee: $59K · Travel and Lodging: $48K · Food and Beverage: $32K · Education: $1,569 · Honoraria: $1,500 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $945.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $226,751.25 |
| Consulting Fee | $58,638.78 |
| Travel and Lodging | $48,221.27 |
| Food and Beverage | $31,662.28 |
| Education | $1,569.13 |
| Honoraria | $1,500.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $945.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $185,698.64 | 2021-2025 | Ingrezza, Ongentys |
| Abbvie INC. | $73,213.19 | 2021-2025 | |
| Ucb, INC. | $61,127.05 | 2021-2025 | Rystiggo, Nayzilam, Briviact |
| Argenx US, INC. | $19,935.01 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Amgen INC. | $18,518.53 | 2021-2025 | Uplizna, Aimovig |
| Genentech USA, INC. | $16,427.87 | 2021-2025 | Ocrevus, Ocrevus Zunovo, Enspryng |
| Janssen Pharmaceuticals, INC | $16,322.74 | 2021-2023 | Ponvory |
| Jazz Pharmaceuticals INC. | $13,349.00 | 2022-2025 | |
| Tg Therapeutics, INC. | $11,341.58 | 2024-2025 | |
| Acorda Therapeutics, INC | $8,687.99 | 2021-2024 | Inbrija |
| Astrazeneca Pharmaceuticals Lp | $7,419.03 | 2021-2025 | Wainua |
| Eisai INC. | $4,417.63 | 2021-2025 | |
| Catalyst Pharmaceuticals, INC. | $3,360.51 | 2023-2025 | Fycompa |
| Allergan, INC. | $3,064.42 | 2021 | |
| Biogen, INC. | $2,577.93 | 2021-2025 | Vumerity, Tysabri, Leqembi |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $2,313.96 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $2,269.48 | 2021-2025 | |
| Horizon Therapeutics Plc | $1,694.89 | 2021-2023 | Uplizna |
| Amneal Pharmaceuticals LLC | $1,487.22 | 2021-2025 | Ongentys 50mg Capsules 30, Ongentys, Rytary |
| Sk Life Science, INC. | $1,126.72 | 2021-2025 | |
| Celgene Corporation | $1,047.65 | 2021-2025 | Zeposia |
| Csl Behring | $1,043.28 | 2021-2025 | Hizentra |
| Pfizer INC. | $1,017.48 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $936.41 | 2021-2025 | Nuplazid |
| Lundbeck LLC | $647.50 | 2021-2025 | Vyepti, Rexulti |
| Lilly USA, LLC | $640.31 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Otsuka America Pharmaceutical, INC. | $452.65 | 2021-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $392.57 | 2023-2025 | Hyqvia, Ninlaro, Gammagard |
| Biohaven Pharmaceuticals, INC. | $352.66 | 2021 | |
| Mdd US Operations, LLC | $322.79 | 2021-2025 | Gocovri, Gocovri, Qelbree |
| Teva Pharmaceuticals USA, INC. | $320.64 | 2021-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Alexion Pharmaceuticals, INC. | $303.41 | 2021-2025 | Ultomiris, Soliris |
| Alnylam Pharmaceuticals INC. | $293.85 | 2023-2025 | Amvuttra |
| Biohaven Pharmaceutical Holding Company Ltd. | $257.43 | 2022 | |
| Genentech, INC. | $215.20 | 2023-2024 | Ocrevus |
| Scilex Pharmaceuticals INC. | $202.07 | 2024-2025 | |
| Grifols USA, LLC | $189.11 | 2022-2025 | Gamunex-C |
| Mallinckrodt Hospital Products INC. | $188.07 | 2021-2024 | Acthar |
| Axsome Therapeutics, INC. | $179.64 | 2025 | Symbravo, Auvelity |
| Impel Pharmaceuticals INC. | $177.66 | 2023 | Trudhesa |
| Octapharma USA, INC. | $141.32 | 2023-2025 | Panzyga |
| Janssen Biotech, INC. | $129.54 | 2025 | |
| Ani Pharmaceuticals, INC. | $119.18 | 2024 | Purified Cortrophin Gel |
| Tanabe Pharma America, INC. | $93.67 | 2023-2025 | Radicava |
| Neurelis, INC. | $84.39 | 2023-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $80.87 | 2024-2025 | Ponvory, Fanapt |
| Supernus Pharmaceuticals, INC. | $71.37 | 2022-2023 | |
| Aucta Pharmaceuticals, INC. | $70.79 | 2025 | Motpoly Xr |
| Cardinal Health 200 LLC | $64.26 | 2023 | |
| Azurity Pharmaceuticals, INC. | $55.00 | 2023 | Horizant |
| Arbor Pharmaceuticals, INC. | $41.38 | 2021-2022 | |
| Novo Nordisk INC | $40.64 | 2021 | |
| Janssen Scientific Affairs, LLC | $40.62 | 2022 | |
| Avanir Pharmaceuticals, INC. | $36.49 | 2022 | |
| Xeris Pharmaceuticals, INC. | $36.03 | 2023 | Keveyis |
| Genzyme Corporation | $32.73 | 2023-2025 | |
| Cycle Pharmaceuticals INC | $22.28 | 2024 | Tascenso Odt |
| Merz Pharmaceuticals, LLC | $20.79 | 2023 | Xeomin |
| Livanova USA, INC. | $20.50 | 2024 | Vns Therapy Sentiva Model 1000 Generator |
| Life Molecular Imaging Ltd | $20.24 | 2024 | Neuraceq |
| Tonix Medicines, INC. | $19.05 | 2025 | Tonmya |
| Ipsen Biopharmaceuticals, INC | $18.04 | 2025 | Dysport |
| Kedrion Biopharma, INC. | $15.89 | 2024 | Gammaked, Koate, Kedrab |
| Boston Scientific Corporation | $11.95 | 2021 | |
| Corium, LLC | $5.61 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.